Enanta is committed to developing new treatments for viral infections and liver diseases. Enanta has active clinical trials in areas including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and in early 2022 will begin a Phase 1 study in SARS-CoV-2 (COVID-19).
If you are a healthcare professional interested in learning more about Enanta’s clinical trials, please contact: Nathalie Adda, MD at nadda@enanta.com.
Learn more about any of our clinical trials described below by clicking the ClinicalTrials.gov. identifier listed below the description of the trial.
Respiratory Syncytial Virus
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)
Clinicaltrials.gov Identifier: NCT04196101
To visit the clinical trial website for RSVP!, click here
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of EDP-938 in Hematopoietic Cell Transplant Recipients with Acute RSV Infection and Symptoms of Upper Respiratory Tract Infection (RSVTx)
ClinicalTrials.gov Identifier: NCT04633187
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate EDP-938 in Regimens in Subjects Aged 28 Days to 24 Months Infected with Respiratory Syncytial Virus (RSV) (RSVPEDs to initiate in Q1 2021)
ClinicalTrials.gov Identifier: NCT04816721
To visit the clinical trial website for RSVPEDs, click here